Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Angeles Alvarez Secord et al.|The Lancet Oncology|2019Cited by 533
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitizationUpasana Ray, Viji Shridhar, Eleftheria Kalogera et al.|Journal of Experimental & Clinical Cancer Research|2021Cited by 25
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Clinical Cancer Research|2024Cited by 15
Data from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Unknown|2024Cited by 0
Supplementary Figure S1 from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Matthew S. Block, Wendy K. Nevala et al.|Unknown|2024Cited by 0